AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Thomson Reuters (TRI.TO) closed at CAD244.87 on August 21, 2025, with a 0.18% rise. The stock traded at a volume of 0.17 billion, ranking 488th in market activity. Analysts remain cautiously optimistic, with CIBC upgrading its rating to "Outperformer" and Scotiabank revising its outlook to "Sector Outperform." Earnings estimates for Q3 2025 show a consensus of CAD0.82 per share, aligning with historical performance that has consistently exceeded expectations by 3-7% over the past year.
Revenue forecasts for 2025 indicate a projected CAD7.49 billion, reflecting a 3.25% year-over-year growth. Analyst price targets range from CAD235.52 to CAD311.67, with an average of CAD275.92. While the stock remains below its 52-week high, upward revisions in EPS estimates over the last 30 days suggest improving confidence in near-term results. The sector outperform rating from multiple brokers indicates a strategic shift in positioning compared to mid-2025
Recent revisions show 7 analysts raised Q3 2025 EPS expectations within the last week, while 6 maintained their projections. This contrasts with 7 downgrades in the same period, highlighting divergent views on short-term performance. The stock's 12-month target of CAD4.36 per share for 2026 implies a 12.87% growth rate, outpacing the S&P 500's projected 13.44% but lagging behind its own historical 13.44% growth
Backtesting of a volume-based strategy from 2022 showed mixed results for the sector. Buying the top 500 stocks by daily trading volume and holding for one day generated a 1.98% average daily return, with a 7.61% total return over 365 days. The strategy achieved a Sharpe ratio of 0.94 but experienced a maximum drawdown of -29.16%, underscoring market volatility risks during downturns

Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Dec.17 2025

Dec.17 2025

Dec.17 2025

Dec.16 2025

Dec.16 2025
Daily stocks & crypto headlines, free to your inbox
Comments
No comments yet